The Technical Analyst
MeiraGTx Holdings PLC [MGTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
MeiraGTx Holdings PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-3.09% $4.71
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 299.54 mill |
| EPS: | -1.490 |
| P/E: | -3.16 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 63.60 mill |
| Avg Daily Volume: | 0.148 mill |
| RATING 2024-04-25 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.16 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.54x |
| Company: PE -3.16 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.37 - 5.05 ( +/- 7.20%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-05 | Forbes Alexandria | Sell | 1 000 | Ordinary Shares |
| 2024-03-12 | Forbes Alexandria | Sell | 2 000 | Ordinary Shares |
| 2024-02-29 | Giroux Richard | Sell | 13 500 | Ordinary Shares |
| 2024-01-07 | Zeldin Robert K | Sell | 13 773 | Ordinary Shares |
| 2024-01-14 | Giroux Richard | Buy | 25 000 | Ordinary Shares |
| INSIDER POWER |
|---|
| -5.93 |
| Last 100 transactions |
| Buy: 8 402 826 | Sell: 8 030 781 |
Forecast:
16:00 - $4.71
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.71
Forecast 2: 16:00 - $4.71
Forecast 3: 16:00 - $4.71
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.71 (-3.09% ) |
| Volume | 0.114 mill |
| Avg. Vol. | 0.148 mill |
| % of Avg. Vol | 77.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MGTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $6.26 | N/A | Active |
|---|
MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2024-04-24 16:30:00 - Press Release
Meiragtx To Participate In Upcoming Investor Conferences
London and new york, april 24, 2024 (globe newswire) -- meiragtx holdings plc (nasdaq: mgtx), a vertically integrated, clinical stage gene therapy company, today announced that alexandria forbes, ph.d., president and chief executive officer, will participate in the following investor conferences:
2024-04-18 16:30:00 - Press Release
Meiragtx Announces Oral Presentation At The 2024 American Academy Of Oral Medicine (aaom) Annual Conference
London and new york, april 18, 2024 (globe newswire) -- meiragtx holdings plc (nasdaq: mgtx), a vertically integrated, clinical stage gene therapy company, today announced the company gave an oral presentation at the american academy of oral medicine annual conference, being held from april 16-20, 2024, at the hyatt regency grand cypress in orlando, fl.
2024-03-14 08:30:00 - Press Release
Meiragtx Reports Fourth Quarter And Full Year 2023 Financial And Operational Results And Recent Business Updates
- company aligned with fda on requirements for ongoing phase 2 aquax2 clinical trial for grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential bla filing
2023-12-21 07:00:00 - Press Release
Meiragtx Announces Asset Purchase Agreement Involving Its Aav-rpgr Collaboration For Up To $415 Million
- meiragtx enters into an asset purchase agreement related to botaretigene sparoparvovec (bota-vec, formerly aav-rpgr) for the treatment of x-linked retinitis pigmentosa (xlrp) for a total of up to $415 million
2023-11-21 16:30:00 - Press Release
Meiragtx To Participate In Upcoming Investor Conferences
London and new york, nov. 21, 2023 (globe newswire) -- meiragtx holdings plc (nasdaq:mgtx), a vertically integrated, clinical stage gene therapy company, today announced that alexandria forbes, ph.d., president and chief executive officer, will participate in the following investor conferences:
Latest News
2024-04-24 16:30:00 - GlobeNewsWire
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
2024-03-14 10:46:12 - Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.58 per share a year ago.
2024-01-10 10:32:52 - Zacks Investment Research
MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions
MeiraGTx (MGTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-01-02 13:32:08 - Zacks Investment Research
MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why
MeiraGTx's (MGTX) shares surge on the sale of rights for a rare ocular disease gene therapy for up to $ 415 million. This funding helps MGTX extend its cash runway into mid-2026.
2023-12-25 11:16:03 - Zacks Investment Research
Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 221.8% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-11-21 16:30:00 - GlobeNewsWire
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
2023-10-30 11:43:54 - Proactive Investors
MeiraGTx shares take off on $30M investment by Sanofi
MeiraGTx Holdings PLC (NASDAQ:MGTX) shares gained more than 25% after it announced Sanofi SA (ADR) (NYSE:SNY), a pharma giant best known for its vaccines, is purchasing 4 million of the gene company's shares at a price of $7.50 per share for a total $30 million investment. MeiraGTx stock was up 25.4% at US$4.64 late morning on Monday, while Sanofi shares gained 3.5% at US$44.63.
2023-10-30 08:28:00 - Market Watch
MeiraGTx shares jump as Sanofi invests in gene therapy
Shares of MeiraGTx Holdings PLC MGTX, -4.88% jumped 14% premarket on Monday after the gene therapy company announced that French drugmaker Sanofi SNY, -19.13% has made a $30 million investment.
2023-08-10 10:46:53 - Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.76 per share a year ago.
2023-06-29 05:23:04 - Zacks Investment Research
MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock?
MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.